CDO

Data quality takes centre stage as 70 senior data leaders set to gather at CDO BFSI Exchange 2024

Retrieved on: 
Wednesday, September 11, 2024
Research, Allianz, AI, CDO, Fintech, HSBC, Pantheon Ventures, London Stock Exchange Group, Bank of England, Bank, Mastercard, Tandem Money, Insurance, WNS, Machine learning, Admiral, BFSI, Architecture, Cryptocurrency

With research conducted by the CDO BFSI Exchange revealing data quality as the top investment priority for data leaders in the BFSI sector over the coming 6-12 months, improving data quality will be a key theme discussed at this year's event.

Key Points: 
  • With research conducted by the CDO BFSI Exchange revealing data quality as the top investment priority for data leaders in the BFSI sector over the coming 6-12 months, improving data quality will be a key theme discussed at this year's event.
  • Taking place on 11-12 November at the Hilton Syon Park in London, the CDO BFSI Exchange will unite 70 of the most senior data leaders from the UK's banking, insurance, and financial services sectors.
  • Altair, DBT Labs, Informatica, Reltio, Treasure Data and WNS Analytics are among the vendors having already secured their participation in the CDO BFSI Exchange.
  • The conference agenda for the CDO BFSI Exchange has been carefully curated after thorough market research with the BFSI sector's leading data experts.

Powering Enterprise AI: BlueCloud's Unique Approach to Building Cloud-Based Enterprise-Grade Data Foundation

Retrieved on: 
Tuesday, September 10, 2024
Cloud, Enterprise, Environment, Snowflake, AI, Empowerment, MIT, Heart, Organization, Charge, Generative, Synthetic media, Partnership, CDO, Ecosystem

TAMPA, Fla. , Sept. 10, 2024 /PRNewswire-PRWeb/ -- Today's enterprise data is evolving rapidly to meet the increasing demand for the upcoming wave of AI-powered applications. But companies can only unleash the full value of data with a strong core on cloud - the only place where data gains scale, agility and the power to drive business reinvention. Without this foundation, Gartner predicts that by 2025, 80% of organizations trying to scale their digital business will fail due to inadequate data and analytics governance. "Strong and modern data foundation has become a critical driver of Enterprise AI", explains Kerem Koca, CEO of BlueCloud. However, he also warns about potential limitation when managed poorly: "Data has become bigger, more complex, more siloed and difficult to unlock".

Key Points: 
  • "Strong and modern data foundation has become a critical driver of Enterprise AI", explains Kerem Koca, CEO of BlueCloud .
  • Building a robust data strategy is crucial for leveraging AI effectively, as quality data is essential for AI to deliver results.
  • Now is the time to embrace a modern data foundation on cloud and unlock your data for AI."
  • (2)
    The main obstacles to building a strong data foundation often include outdated data infrastructures and the lack of a modern data stack.

AI and Big Data Expo Europe Countdown: Just 1 Month to Go!

Retrieved on: 
Monday, September 2, 2024
OEM, Intelligence, AI, Rod Evans, NVIDIA, KLM, Data, IOT, OutSystems, Government, Operational technology, VCS, ING, RAI Amsterdam, Software, Developer, Big data, CDO, Exhibition, Retail

Amsterdam, Sept 2, 2024 - (ACN Newswire) - AI and Big Data Expo Europe, the premier event for AI and Big Data enthusiasts, innovators, and industry leaders, is just over one month away.

Key Points: 
  • Amsterdam, Sept 2, 2024 - (ACN Newswire) - AI and Big Data Expo Europe, the premier event for AI and Big Data enthusiasts, innovators, and industry leaders, is just over one month away.
  • - Unmatched Networking Opportunities: With over 7,000 attendees expected, the AI and Big Data Expo offers unparalleled opportunities for networking.
  • This multi-event format ensures attendees can explore the intersection of AI, big data, and other emerging technologies.
  • Secure your free pass today by visiting AI and Big Data Expo Europe Registration.

Introducing the Future of Healthcare: CharmHealth Announces Winners of the 2024 Innovation Challenge

Retrieved on: 
Thursday, August 29, 2024
Health Technology, Artificial Intelligence, Health Insurance, Parenting, Biotechnology, Children, Consulting, Baby, Maternity, Health, Professional Services, Entrepreneur, Family, Consumer, Apps, Applications, Small Business, Software, Other Health, Practice Management, Data Management, Managed Care, General Health, Technology, Business, Start-Up, Hospitals, Hope, Conference, Second Place, Third place, Generative, Ecosystem, Incubator, First Place, CDO, Population health, EHR, Multimedia, Innovation, Synthetic media, Cryptocurrency

CharmHealth , a leader in healthcare technology solutions for providers, today announced the winners of its 2024 Innovation Challenge .

Key Points: 
  • CharmHealth , a leader in healthcare technology solutions for providers, today announced the winners of its 2024 Innovation Challenge .
  • View the full release here: https://www.businesswire.com/news/home/20240829245622/en/
    The winners of the 2024 CharmHealth Innovation Challenge stand alongside CharmHealth founder and CEO, Pramila Srinivasan.
  • The 2024 Innovation Challenge winners are:
    First Place, $10,000 prize: Tina John, founder of Avira Health , supporting postpartum mothers in early stages of motherhood and breastfeeding.
  • CharmHealth’s Innovation Challenge is known for spurring an active knowledge exchange and sparking conversations that will influence the future of health.

IBM Study: C-Suite Confidence in Delivering Basic IT Services Wanes, While Tech CxOs Focus on Gen AI Demands

Retrieved on: 
Wednesday, August 21, 2024
Investment, CFO, Organization, Operational technology, Tech, CDO, Business value, CFOS, IBV, IBM, IBM Consulting, Senior, Privacy, Management

As tech CxOs prioritize generativeAI-ready infrastructure investments, two-thirds of surveyed CEOs cite that a strong tech CxO and CFO collaboration is critical to their organization's success.

Key Points: 
  • As tech CxOs prioritize generativeAI-ready infrastructure investments, two-thirds of surveyed CEOs cite that a strong tech CxO and CFO collaboration is critical to their organization's success.
  • "Tech leaders today are grappling with multiple business demands, made even more complicated by the rise of generative AI.
  • 41% of tech CxOs surveyed reported an increase in their concerns about regulation and compliance as a barrier to generative AI over the last six months.
  • 63% of tech CxOs surveyed agree that their competitiveness will hinge on their ability to attract, develop and retain top talent.

Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences

Retrieved on: 
Monday, August 12, 2024
Therapy, Testicular cancer, Congress, Study Group, CDO, EMA, The German, CTA, INN, Ototoxicity, Hearing loss, Trial of the century, Gesellschaft mit beschränkter Haftung, Patient, Culture, Medical device, Clinical trial, Summit, European Medicines Agency, Cisplatin, Pharmaceutical industry

The PROHEAR study is a placebo-controlled Phase 2a study with split-body design investigating the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose, cisplatin-based chemotherapy regimens (cis-Pt ≥300 mg/m2).

Key Points: 
  • The PROHEAR study is a placebo-controlled Phase 2a study with split-body design investigating the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose, cisplatin-based chemotherapy regimens (cis-Pt ≥300 mg/m2).
  • On September 22, Dr. Dyhrfjeld-Johnsen will be presenting the Phase 2 PROHEAR clinical study of ACOU085 to an international audience of clinical specialists at the 36th World Congress of Audiology in Paris, France during the Clinical Trials in Audiology and Otoneurology session.
  • "We are thrilled by the invitations to present our ongoing PROHEAR study testing the otoprotective efficacy of ACOU085 against cisplatin-induced hearing loss to the international clinical community and our industry peers.
  • ACOU085 (INN: Bimokalner) is a first-in-class, small-molecule, etiology-agnostic otoprotective drug candidate delivered using standard, transtympanic administration of a proprietary, slow-release gel formulation.

Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming conferences

Retrieved on: 
Monday, August 12, 2024
Therapy, Testicular cancer, Congress, Study Group, CDO, EMA, The German, CTA, INN, Ototoxicity, Hearing loss, Trial of the century, Gesellschaft mit beschränkter Haftung, Patient, Culture, Medical device, Clinical trial, Summit, European Medicines Agency, Cisplatin, Pharmaceutical industry

The PROHEAR study is a placebo-controlled Phase 2a study with split-body design investigating the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose, cisplatin-based chemotherapy regimens (cis-Pt ≥300 mg/m2).

Key Points: 
  • The PROHEAR study is a placebo-controlled Phase 2a study with split-body design investigating the otoprotective efficacy of ACOU085 in patients with testicular cancer undergoing high-dose, cisplatin-based chemotherapy regimens (cis-Pt ≥300 mg/m2).
  • On September 22, Dr. Dyhrfjeld-Johnsen will be presenting the Phase 2 PROHEAR clinical study of ACOU085 to an international audience of clinical specialists at the 36th World Congress of Audiology in Paris, France during the Clinical Trials in Audiology and Otoneurology session.
  • "We are thrilled by the invitations to present our ongoing PROHEAR study testing the otoprotective efficacy of ACOU085 against cisplatin-induced hearing loss to the international clinical community and our industry peers.
  • ACOU085 (INN: Bimokalner) is a first-in-class, small-molecule, etiology-agnostic otoprotective drug candidate delivered using standard, transtympanic administration of a proprietary, slow-release gel formulation.

A carry crash also kicked off the global financial crisis 17 years ago — here’s why it’s unlikely to get as bad this time

Retrieved on: 
Friday, August 9, 2024
Crash, Silicon, Risk, CDO, Bank, Panic, UBS, Silicon Valley Bank, British Academy, History, Research

This is the culprit for the rollercoaster state of markets, many market commentators and journalists have opined.

Key Points: 
  • This is the culprit for the rollercoaster state of markets, many market commentators and journalists have opined.
  • Indeed it also played a role in kicking off the credit crunch and resulting global financial crisis in 2007-08.
  • Then Japanese stocks took a bigger battering on Monday, posting the biggest ever one-day drop in the Nikkei, the country’s main share index.
  • Since then, markets have gyrated up and down as traders and investors attempt to understand what is going on.
  • Researchers at Swiss bank UBS estimate that since 2011, more than US$500 billion (£392 billion) in US dollar-yen carry trades have taken place.

Carry trades and financial crises

  • Financial history supports the idea that we should be worried about these carry crashes.
  • My latest book about the history of financial crises, Calming the Storms: the Carry Trade, the Banking School and British Financial Crises Since 1825, shows how they have been involved with every major banking crisis in Britain over the past 200 years.
  • The yen-dollar carry trade also played a role in triggering the global financial crisis of 2007-08.
  • If you’re involved in financial markets, either as investor or investee, the wild ride is not over yet.

AI Futurist and Former Head of Go-To-Market at OpenAI to Keynote at DataDriven24

Retrieved on: 
Wednesday, August 7, 2024
Software, Networks, Internet, Artificial Intelligence, Data Management, Technology, Apps, Applications, Mobile, Wireless, OpenAI, ZS, CIO, CDO, PwC, AWS, Final good, AI, Environment, IHG, Research

At DataDriven24, Zack will demystify AI for attendees, making it accessible and actionable for enterprise leaders navigating today’s dynamic landscape.

Key Points: 
  • At DataDriven24, Zack will demystify AI for attendees, making it accessible and actionable for enterprise leaders navigating today’s dynamic landscape.
  • Kass’ mission is to ensure businesses and governments are active participants in the coming AI-powered future by helping leaders navigate the rapidly evolving environment.
  • While Head of Go To Market at OpenAI, Kass worked at the helm of the team key to channeling OpenAI’s innovative research into tangible business solutions.
  • In addition to the keynotes, DataDriven24 will offer networking opportunities with leading data and AI practitioners, CDOs, CDAOs, and CIO and IT leaders from across the globe.

Bloomin' Blinds Announces New CEO Alongside Debut of Revolutionary Technology Launch

Retrieved on: 
Tuesday, August 6, 2024
CDO, EDI, FDD, Culture, News, Growth, Visualizer, Executive, Partnership, AI, Communication, Sale, KPI, ROI, Family

Together, this sets the stage for rapid development and innovation, allowing Bloomin' Blinds to seamlessly deliver results, profitability, and growth for its franchisees.

Key Points: 
  • Together, this sets the stage for rapid development and innovation, allowing Bloomin' Blinds to seamlessly deliver results, profitability, and growth for its franchisees.
  • Stepping into the CEO role is a natural progression, building on his accomplishments with the company serving as Bloomin' Blinds Executive Vice President.
  • Alongside the CEO announcement is the launch of BloomScale, designed to improve the customer experience while simplifying operations for franchisees and team members.
  • Our goal is to leverage technology to enhance human relationships, and that's exactly what we're doing with this technology platform."